Portfolios of Biomedical HIV Interventions in South Africa: A Cost-Effectiveness Analysis
- 492 Downloads
Recent clinical trials of male circumcision, oral pre-exposure prophylaxis (PrEP), and a vaginal microbicide gel have shown partial effectiveness at reducing HIV transmission, stimulating interest in implementing portfolios of biomedical prevention programs.
To evaluate the effectiveness and cost-effectiveness of combination biomedical HIV prevention and treatment scale-up in South Africa, given uncertainty in program effectiveness.
Dynamic HIV transmission and disease progression model with Monte Carlo simulation and cost-effectiveness analysis.
Men and women aged 15 to 49 years in South Africa.
HIV screening and counseling, antiretroviral therapy (ART), male circumcision, PrEP, microbicide, and select combinations.
HIV incidence, prevalence, discounted costs, discounted quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios.
Providing half of all uninfected persons with PrEP averts 28 % of future HIV infections for $9,000/QALY gained, but the affordability of such a program is questionable. Given limited resources, annual HIV screening and ART utilization by 75 % of eligible infected persons could avert one-third of new HIV infections, for approximately $1,000/QALY gained. Male circumcision is more cost-effective, but disproportionately benefits men. A comprehensive portfolio of expanded screening, ART, male circumcision, microbicides, and PrEP could avert 62 % of new HIV infections, reducing HIV prevalence from a projected 14 % to 10 % after 10 years. This strategy doubles treatment initiation and adds 31 million QALYs to the population. Despite uncertainty in program effectiveness, a comprehensive portfolio costs less than $10,000/QALY gained in 33 % of simulation iterations and less than $30,000/QALY gained in 90 % of iterations, assuming an annual microbicide cost of $100.
A portfolio of modestly-effective biomedical HIV prevention programs, including male circumcision, vaginal microbicides, and oral PrEP, could substantially reduce HIV incidence and prevalence in South Africa and be likely cost-effective. Given limited resources, PrEP is the least cost-effective intervention of those considered.
KEY WORDSHIV epidemic mathematical model simulation cost-effectiveness analysis combination HIV prevention
We wish to thank Margaret Brandeau and Edward Kaplan for their valuable suggestions for improving the manuscript. This study was supported in part by a grant from the National Institute on Drug Abuse (R01-DA15612). An earlier version of this paper was presented at the Society for Medical Decision Making Annual Meeting in October 2011.
Conflicts Of Interest
The authors declare that they have no conflicts of interest.
Elisa F. Long: study design, model building and coding, data analysis, data interpretation, writing of the manuscript.
Robert R. Stavert: literature search, data collection, data analysis.
- 4.Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global AIDS epidemic. Geneva 2010.Google Scholar
- 5.Kates J, Boortz K, Lief E, Avila C, Bobet G. Financing the Response to AIDS in Low- and Middle-Income Countries: International Assistance from the G8, European Commission and Other Donor Governments in 2009, Washington, DC: Kaiser Family Foundation and UNAIDS; 2010.Google Scholar
- 6.Joint United Nations Programme on HIV/AIDS (UNAIDS). World AIDS Day Report. Geneva 2011.Google Scholar
- 10.Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane database of systematic reviews (Online). 2009(2):CD003362.Google Scholar
- 19.National Institute of Allergy and Infectious Diseases (NIAID). HIV Study Named 2011 Breakthrough of the Year by Science. 2011; http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052Breakthrough.aspx. Accessed January 25, 2013.
- 27.Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.Google Scholar
- 28.Shisana O, Rehle T, Simbayi L, et al. South African national HIV prevalence, HIV incidence, behaviour and communication survey, 2008: A turning tide among teenagers? Cape Town: HSRC Press; 2009.Google Scholar
- 29.South Africa Department of Health. Country progress report on the Declaration of Commitment on HIV/AIDS. Pretoria: Department of Health; 2010.Google Scholar
- 30.World Health Organization Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development. Geneva 2001.Google Scholar
- 34.Shisana O, Rehle T, Simbayi L, et al. South African national HIV prevalence, HIV incidence, behaviour and communication survey, 2005. Cape Town: HSRC Press; 2005.Google Scholar
- 35.South Africa Department of Health, Medical Research Council. South Africa demographic and health survey 2003. Pretoria: Department of Health; 2007.Google Scholar